Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: Results of a large observational study

A. Guerrieri-Gonzaga; E. Botteri; M. Lazzeroni; N. Rotmensz; A. Goldhirsch; C. Varricchio; D. Serrano; M. Cazzaniga; F. Bassi; A. Luini; V. Bagnardi; G. Viale; S. Mora; G. Bollani; E. Albertazzi; B. Bonanni; A. Decensi

doi:10.1093/annonc/mdp408

Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: Results of a large observational study

A. Guerrieri-Gonzaga, E. Botteri, M. Lazzeroni, N. Rotmensz, A. Goldhirsch, C. Varricchio, D. Serrano, M. Cazzaniga, F. Bassi, A. Luini, V. Bagnardi, G. Viale, S. Mora, G. Bollani, E. Albertazzi, B. Bonanni, A. Decensi

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Tamoxifen's cost-benefit ratio for breast ductal intraepithelial neoplasia (DIN) is unclear. Since low-dose tamoxifen showed a favorable modulation of breast cancer biomarkers in phase II trials, a monoinstitutional cohort of women with DIN treated with low-dose tamoxifen or no systemic treatment was analyzed. Patients and methods: A total of 309 patients with DIN received low-dose tamoxifen as part of institutional guidelines and were compared with 371 patients with DIN who received no systemic treatment after surgery. Results: Women with estrogen receptor (ER)/progesterone receptor (PgR) >50% DIN who were not treated had a higher incidence of breast events than women on tamoxifen [hazard ratio (HR) 1.76; 95% confidence interval (CI) 1.00-3.12] or women with ER/PgR 50% DIN, recurrence was higher in PgR ≥50% DIN than in PgR

Original language	English
Pages (from-to)	949-954
Number of pages	6
Journal	Annals of Oncology
Volume	21
Issue number	5
DOIs	https://doi.org/10.1093/annonc/mdp408
Publication status	Published - Oct 25 2009

Keywords

Breast cancer
DCIS
Ductal intraepithelial neoplasia
Low-dose tamoxifen

ASJC Scopus subject areas

Oncology
Hematology

Access to Document

10.1093/annonc/mdp408

Cite this

Guerrieri-Gonzaga, A., Botteri, E., Lazzeroni, M., Rotmensz, N., Goldhirsch, A., Varricchio, C., Serrano, D., Cazzaniga, M., Bassi, F., Luini, A., Bagnardi, V., Viale, G., Mora, S., Bollani, G., Albertazzi, E., Bonanni, B., & Decensi, A. (2009). Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: Results of a large observational study. Annals of Oncology, 21(5), 949-954. https://doi.org/10.1093/annonc/mdp408

Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia : Results of a large observational study. / Guerrieri-Gonzaga, A.; Botteri, E.; Lazzeroni, M.; Rotmensz, N.; Goldhirsch, A.; Varricchio, C.; Serrano, D.; Cazzaniga, M.; Bassi, F.; Luini, A.; Bagnardi, V.; Viale, G.; Mora, S.; Bollani, G.; Albertazzi, E.; Bonanni, B.; Decensi, A.

In: Annals of Oncology, Vol. 21, No. 5, 25.10.2009, p. 949-954.

Research output: Contribution to journal › Article › peer-review

Guerrieri-Gonzaga, A, Botteri, E, Lazzeroni, M, Rotmensz, N, Goldhirsch, A, Varricchio, C, Serrano, D, Cazzaniga, M, Bassi, F , Luini, A, Bagnardi, V, Viale, G , Mora, S, Bollani, G, Albertazzi, E, Bonanni, B & Decensi, A 2009, 'Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: Results of a large observational study', Annals of Oncology, vol. 21, no. 5, pp. 949-954. https://doi.org/10.1093/annonc/mdp408

Guerrieri-Gonzaga, A. ; Botteri, E. ; Lazzeroni, M. ; Rotmensz, N. ; Goldhirsch, A. ; Varricchio, C. ; Serrano, D. ; Cazzaniga, M. ; Bassi, F. ; Luini, A. ; Bagnardi, V. ; Viale, G. ; Mora, S. ; Bollani, G. ; Albertazzi, E. ; Bonanni, B. ; Decensi, A. / Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia : Results of a large observational study. In: Annals of Oncology. 2009 ; Vol. 21, No. 5. pp. 949-954.

@article{d11d11fcb8734f648962c1672af1a15f,

title = "Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: Results of a large observational study",

abstract = "Background: Tamoxifen's cost-benefit ratio for breast ductal intraepithelial neoplasia (DIN) is unclear. Since low-dose tamoxifen showed a favorable modulation of breast cancer biomarkers in phase II trials, a monoinstitutional cohort of women with DIN treated with low-dose tamoxifen or no systemic treatment was analyzed. Patients and methods: A total of 309 patients with DIN received low-dose tamoxifen as part of institutional guidelines and were compared with 371 patients with DIN who received no systemic treatment after surgery. Results: Women with estrogen receptor (ER)/progesterone receptor (PgR) >50% DIN who were not treated had a higher incidence of breast events than women on tamoxifen [hazard ratio (HR) 1.76; 95% confidence interval (CI) 1.00-3.12] or women with ER/PgR 50% DIN, recurrence was higher in PgR ≥50% DIN than in PgR ",

keywords = "Breast cancer, DCIS, Ductal intraepithelial neoplasia, Low-dose tamoxifen",

author = "A. Guerrieri-Gonzaga and E. Botteri and M. Lazzeroni and N. Rotmensz and A. Goldhirsch and C. Varricchio and D. Serrano and M. Cazzaniga and F. Bassi and A. Luini and V. Bagnardi and G. Viale and S. Mora and G. Bollani and E. Albertazzi and B. Bonanni and A. Decensi",

year = "2009",

month = oct,

day = "25",

doi = "10.1093/annonc/mdp408",

language = "English",

volume = "21",

pages = "949--954",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "NLM (Medline)",

number = "5",

}

TY - JOUR

T1 - Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia

T2 - Results of a large observational study

AU - Guerrieri-Gonzaga, A.

AU - Botteri, E.

AU - Lazzeroni, M.

AU - Rotmensz, N.

AU - Goldhirsch, A.

AU - Varricchio, C.

AU - Serrano, D.

AU - Cazzaniga, M.

AU - Bassi, F.

AU - Luini, A.

AU - Bagnardi, V.

AU - Viale, G.

AU - Mora, S.

AU - Bollani, G.

AU - Albertazzi, E.

AU - Bonanni, B.

AU - Decensi, A.

PY - 2009/10/25

Y1 - 2009/10/25

N2 - Background: Tamoxifen's cost-benefit ratio for breast ductal intraepithelial neoplasia (DIN) is unclear. Since low-dose tamoxifen showed a favorable modulation of breast cancer biomarkers in phase II trials, a monoinstitutional cohort of women with DIN treated with low-dose tamoxifen or no systemic treatment was analyzed. Patients and methods: A total of 309 patients with DIN received low-dose tamoxifen as part of institutional guidelines and were compared with 371 patients with DIN who received no systemic treatment after surgery. Results: Women with estrogen receptor (ER)/progesterone receptor (PgR) >50% DIN who were not treated had a higher incidence of breast events than women on tamoxifen [hazard ratio (HR) 1.76; 95% confidence interval (CI) 1.00-3.12] or women with ER/PgR 50% DIN, recurrence was higher in PgR ≥50% DIN than in PgR

AB - Background: Tamoxifen's cost-benefit ratio for breast ductal intraepithelial neoplasia (DIN) is unclear. Since low-dose tamoxifen showed a favorable modulation of breast cancer biomarkers in phase II trials, a monoinstitutional cohort of women with DIN treated with low-dose tamoxifen or no systemic treatment was analyzed. Patients and methods: A total of 309 patients with DIN received low-dose tamoxifen as part of institutional guidelines and were compared with 371 patients with DIN who received no systemic treatment after surgery. Results: Women with estrogen receptor (ER)/progesterone receptor (PgR) >50% DIN who were not treated had a higher incidence of breast events than women on tamoxifen [hazard ratio (HR) 1.76; 95% confidence interval (CI) 1.00-3.12] or women with ER/PgR 50% DIN, recurrence was higher in PgR ≥50% DIN than in PgR

KW - Breast cancer

KW - DCIS

KW - Ductal intraepithelial neoplasia

KW - Low-dose tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=77953337169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953337169&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdp408

DO - 10.1093/annonc/mdp408

M3 - Article

C2 - 19858087

AN - SCOPUS:77953337169

VL - 21

SP - 949

EP - 954

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 5

ER -

Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: Results of a large observational study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this